Understand the source comparison
AHK-Cu vs Traditional Hair Loss Treatments
The AHK-Cu protocol operates through a fundamentally different mechanism than finasteride or minoxidil. Finasteride blocks the enzyme 5α-reductase systemically, reducing DHT conversion throughout the body. Minoxidil is a potassium channel opener that increases
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The AHK-Cu protocol operates through a fundamentally different mechanism than finasteride or minoxidil. Finasteride blocks the enzyme 5α-reductase systemically, reducing DHT conversion throughout the body. Minoxidil is a potassium channel opener that increases dermal blood flow. AHK-Cu neither suppresses hormones nor dilates blood vessels. It delivers copper ions chelated to the AHK tripeptide sequence, which triggers several downstream effects: increased vascular endothelial growth factor (VEGF) expression around the follicle, inhibition of transforming growth factor-beta (TGF-β1) which shortens anagen phase, and localized 5α-reductase inhibition without systemic hormonal suppression.
- Clinical trials comparing AHK-Cu to minoxidil 2% show comparable density improvement at 24 weeks (11.2% vs 8.1%), but AHK-Cu demonstrates better tolerability. No vasodilatory side effects, no initial shedding phase, and no tachyphylaxis (loss of response over time). The trade-off: AHK-Cu requires consistent nightly application and takes longer to show visible results. Most patients report noticing thickness changes only after week 14–16, compared to week 8–10 for minoxidil responders.
- Research-grade peptides like those available through Real Peptides undergo third-party purity verification and are manufactured under GMP standards, which matters for peptide stability. Copper chelation efficiency drops sharply when the AHK sequence contains even trace impurities from synthesis byproducts.